BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster ...

Detailed price information for Briacell Therapeutics Corp (BCTX-Q) from The Globe and Mail including charting and trades.

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced that its Trial in Progress abstract has been ...

Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, today provided additional details on ...

Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through its proprietary fascin inhibitor technology, today ...

An engineered viral protein enhanced the anticancer function of T cells in mice ... contained the regions responsible for binding to LCK but not for affecting T cell activity. Treating cultured T ...

Updated results of fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): a ...

Advances in multi-omics, artificial intelligence (AI), deep learning (DL), ageing biomarkers, precision imaging, ageing clocks, robotics, and smart technologies have enabled researchers to ...

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...

Ovarian cancer is an abnormal cell growth (tumour) arising in the ovary. The majority of ovarian cancers are epithelial and develop in women over 50. Screening is highly recommended in women with ...

Find more information on the Altmetric Attention Score and how the score is calculated. DNA topoisomerase I (Top1) is often exploited as an imperative anticancer chemotherapeutic target due to its ...